-
公开(公告)号：US11795478B2
公开(公告)日：2023-10-24
申请号：US17742221
申请日：2022-05-11
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Virginia Ammendola , Stefania Capone , Stefano Colloca , Antonella Folgori , Rossella Merone
CPC classification number: C12N15/86 , A61K39/12 , A61K39/21 , A61P31/14 , A61P31/18 , C07K14/005 , A61K2039/572 , C12N2710/10343 , C12N2740/16034 , C12N2740/16234 , C12N2760/20134
Abstract: The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.
-
公开(公告)号：US20170044571A1
公开(公告)日：2017-02-16
申请号：US15339225
申请日：2016-10-31
Applicant: The Government of the United States of America as Represented by the Secretary of the Department of , GlaxoSmithKline Biologicals SA
Inventor： Nancy J. Sullivan , Gary J Nabel , Clement Asiedu , Cheng Cheng , Alfredo Nicosia , Riccardo Cortese , Virginia Ammendola , Stefano Colloca
IPC: C12N15/86 , C12N7/00 , C07K14/005
Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).
Abstract translation: 本发明提供用于诱导免疫应答的疫苗和针对用于人类预防性疫苗的禽流感病毒感染的保护。 特别地，本发明提供了表达来自不同的埃博病毒（EBOV）或马尔堡病毒（MARV）病毒的病毒蛋白的黑猩猩腺病毒载体。
-
公开(公告)号：US11957749B2
公开(公告)日：2024-04-16
申请号：US16772194
申请日：2018-12-14
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Virginia Ammendola , Babak Bayat , Clarisse Lorin , Ventzislav Bojidarov Vassilev , Alessandra Vitelli
CPC classification number: A61K39/292 , A61K39/39 , A61P31/20 , C07K14/005 , C12N7/00 , A61K2039/5254 , A61K2039/5256 , A61K2039/55555 , A61K2039/55572 , A61K2039/55577 , A61K2039/57 , C07K2319/40 , C12N2710/10343 , C12N2710/24143 , C12N2730/10122 , C12N2730/10134
Abstract: The present invention relates to immunogenic compositions and combinations thereof which may find use in immunisation regimens for the treatment of chronic hepatitis B. An immunogenic composition comprises a replication-defective chimpanzee adenoviral (ChAd) vector comprising polynucleotides encoding HBs, HBc human invariant chain (hIi) fused to the HBc. Another immunogenic composition comprises a Modified Vaccinia Virus Ankara (MVA) vector comprising polynucleotides encoding HBs and HBc. Another immunogenic composition comprises recombinant HBs, C-terminal truncated recombinant HBc and an adjuvant containing MPL and QS-21.
-
公开(公告)号：US11414679B2
公开(公告)日：2022-08-16
申请号：US16466683
申请日：2017-12-07
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Virginia Ammendola , Stefania Capone , Stefano Colloca , Antonella Folgori , Rossella Merone
Abstract: The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.
-
公开(公告)号：US10584355B2
公开(公告)日：2020-03-10
申请号：US15339225
申请日：2016-10-31
Applicant: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES , GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Nancy J. Sullivan , Gary J Nabel , Clement Asiedu , Cheng Cheng , Alfredo Nicosia , Riccardo Cortese , Virginia Ammendola , Stefano Colloca
IPC: C12N15/86 , A61K39/12 , C07K14/005 , C12N7/00 , A61K39/00
Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).
-
Patent Agency Ranking
公开(公告)号：US20200149069A1
公开(公告)日：2020-05-14
申请号：US16751470
申请日：2020-01-24
Applicant: The Government of the United States of America as Represented by the Secretary of the Department of , GlaxoSmithKline Biologicals SA
Inventor： Nancy J. Sullivan , Gary J. Nabel , Clement Asiedu , Cheng Cheng , Alfredo Nicosia , Riccardo Cortese , Virginia Ammendola , Stefano Colloca
IPC: C12N15/86 , C12N7/00 , C07K14/005 , A61K39/12
Abstract: This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of Ebolavirus (EBOV) or Marburg virus (MARV).
-
公开(公告)号：US10544192B2
公开(公告)日：2020-01-28
申请号：US15623723
申请日：2017-06-15
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Stefano Colloca , Alfredo Nicosia , Riccardo Cortese, Sr. , Virginia Ammendola , Maria Ambrosio
IPC: C07K14/005 , A61K39/12 , A61K39/235 , C12N7/00 , C12N15/86 , A61K39/00 , A61K48/00
Abstract: The present invention relates to novel adenovirus strains with an improved seroprevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polypeptides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.
-
8.发明申请公开(公告)号：US20180057540A1
公开(公告)日：2018-03-01
申请号：US15623723
申请日：2017-06-15
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Stefano Colloca , Alfredo Nicosia , Riccardo Cortese, Sr. , Virginia Ammendola , Maria Ambrosio
IPC: C07K14/005 , C12N15/86 , A61K39/12 , A61K39/235 , C12N7/00 , A61K39/00 , A61K48/00
CPC classification number: C07K14/005 , A61K39/0011 , A61K39/12 , A61K39/235 , A61K48/00 , A61K2039/525 , A61K2039/5256 , A61K2039/545 , C12N7/00 , C12N15/86 , C12N2710/10321 , C12N2710/10322 , C12N2710/10334 , C12N2710/10343 , C12N2710/16634 , C12N2740/16134 , C12N2770/24234
Abstract: The present invention relates to novel adenovirus strains with an improved seroprevalence. In one aspect, the present invention relates to isolated polypeptides of adenoviral capsid proteins such as hexon, penton and fiber protein and fragments thereof and polynucleotides encoding the same. Also provided is a vector comprising the isolated polynucleotide according to the invention and adenoviruses comprising the isolated polynucleotides or polypeptides according to the invention and a pharmaceutical composition comprising said vector, adenovirus, polypeptide and/or polynucleotide. The invention also relates to the use of the isolated polypeptides, the isolated polypeptides, the vector, the adenoviruses and/or the pharmaceutical composition for the therapy or prophylaxis of a disease.
-
公开(公告)号：US11268108B2
公开(公告)日：2022-03-08
申请号：US16756376
申请日：2018-10-16
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Virginia Ammendola , Stefano Colloca , Alessandra Vitelli
Abstract: Replication competent simian adenoviral vectors are provided for the delivery of exogenous immunogens. Vectors of the invention demonstrate superior replication and expression of exogenous immunogens. They are useful as prophylactic and therapeutic vaccines as well as in gene therapy.
-
公开(公告)号：US11702674B2
公开(公告)日：2023-07-18
申请号：US16973630
申请日：2019-06-11
Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
Inventor： Virginia Ammendola , Stefania Capone , Stefano Colloca , Antonella Folgori , Rossella Merone
CPC classification number: C12N15/86 , A61K39/235 , A61K39/12 , A61K39/21 , A61K2039/5256 , A61P37/04 , C12N2710/10322 , C12N2710/10334 , C12N2710/10343 , C12N2740/16034 , C12N2740/16071
Abstract: The present invention relates to isolated polynucleotide and polypeptide sequences derived from novel chimpanzee adenovirus ChAd157, as well as to recombinant polynucleotides, vectors, adenoviruses, cells and compositions comprising said polynucleotide and polypeptide sequences.
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.013 seconds)
